The Immunoadoptive Cell Therapy Private Limited (ImmunoACT), based in Mumbai, India, on October 13, 2023, announced the Central Drugs Standard Control Organization (CDSCO)’s approval for the use of the country’s first chimeric antigen receptor (CAR-T) cell therapy for the treating relapsed-refractory B-cell lymphoma and leukemia.
Trending
- FG warns 915 communities in 19 states, FCT of critical flood risk [FULL LIST]
- Exabeam named Google unified security recommended partner
- Tinubu orders comprehensive reform of Nigerian football amid NFF crisis
- Ekpa appeals 6-year jail term as Finland seeks longer sentence
- Nvidia CEO shrugs off OpenAI’s chip challenge, says company remains unconcerned
- Advocate warns working mothers against unhealthy social competition
- PCN seals 430 medicine outlets in Yobe
- Otti orders urgent fix for erosion, flood sites in Abia
